Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,763
archived clinical trials in
Colitis

Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  2/13/2013
Pfizer Investigational Site
1519
mi
from 43215
West Jordan, UT
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 2/13/2013
Pfizer Investigational Site
1519
mi
from 43215
West Jordan, UT
Click here to add this to my saved trials
Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis
Diverting Loop Ileostomy and Colonic Lavage: An Alternative To Total Abdominal Colectomy For The Treatment Of Fulminant Clostridium Difficile Colitis. A Randomized Controlled Trial.
Status: Enrolling
Updated:  2/23/2013
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis
Diverting Loop Ileostomy and Colonic Lavage: An Alternative To Total Abdominal Colectomy For The Treatment Of Fulminant Clostridium Difficile Colitis. A Randomized Controlled Trial.
Status: Enrolling
Updated: 2/23/2013
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis
Status: Enrolling
Updated:  3/11/2013
Arkansas Children's Hospital
622
mi
from 43215
Little Rock, AR
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis
Status: Enrolling
Updated: 3/11/2013
Arkansas Children's Hospital
622
mi
from 43215
Little Rock, AR
Click here to add this to my saved trials
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis
Status: Enrolling
Updated:  3/11/2013
Advanced Clinical Research Institute
1962
mi
from 43215
Anaheim, CA
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis
Status: Enrolling
Updated: 3/11/2013
Advanced Clinical Research Institute
1962
mi
from 43215
Anaheim, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis
Status: Enrolling
Updated:  3/11/2013
University of California, San Francisco
2107
mi
from 43215
San Francisco, CA
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis
Status: Enrolling
Updated: 3/11/2013
University of California, San Francisco
2107
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis
Status: Enrolling
Updated:  3/11/2013
Connecticut Children's Medical Center
553
mi
from 43215
Hartford, CT
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis
Status: Enrolling
Updated: 3/11/2013
Connecticut Children's Medical Center
553
mi
from 43215
Hartford, CT
Click here to add this to my saved trials
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis
Status: Enrolling
Updated:  3/11/2013
University of Maryland Medical Center for Children
mi
from 43215
Baltimore, MD
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis
Status: Enrolling
Updated: 3/11/2013
University of Maryland Medical Center for Children
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis
Status: Enrolling
Updated:  3/11/2013
Mayo Clinic Rochester
559
mi
from 43215
Rochester, MN
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis
Status: Enrolling
Updated: 3/11/2013
Mayo Clinic Rochester
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease
Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease
Status: Enrolling
Updated:  3/12/2013
Santa Barbara Cottage Hospital
2042
mi
from 43215
Santa Barbara, CA
Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease
Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease
Status: Enrolling
Updated: 3/12/2013
Santa Barbara Cottage Hospital
2042
mi
from 43215
Santa Barbara, CA
Click here to add this to my saved trials
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
A Phase 1, Randomized, Double-Blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects, in Subjects With Active Ulcerative Colitis, and in Subjects With Active Crohn's Disease.
Status: Enrolling
Updated:  4/3/2013
Clinical Research Facility
1968
mi
from 43215
Glendale, CA
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
A Phase 1, Randomized, Double-Blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects, in Subjects With Active Ulcerative Colitis, and in Subjects With Active Crohn's Disease.
Status: Enrolling
Updated: 4/3/2013
Clinical Research Facility
1968
mi
from 43215
Glendale, CA
Click here to add this to my saved trials
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
A Phase 1, Randomized, Double-Blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects, in Subjects With Active Ulcerative Colitis, and in Subjects With Active Crohn's Disease.
Status: Enrolling
Updated:  4/3/2013
Clinical Research Facility
522
mi
from 43215
Bridgeport, CT
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
A Phase 1, Randomized, Double-Blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects, in Subjects With Active Ulcerative Colitis, and in Subjects With Active Crohn's Disease.
Status: Enrolling
Updated: 4/3/2013
Clinical Research Facility
522
mi
from 43215
Bridgeport, CT
Click here to add this to my saved trials
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
A Phase 1, Randomized, Double-Blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects, in Subjects With Active Ulcerative Colitis, and in Subjects With Active Crohn's Disease.
Status: Enrolling
Updated:  4/3/2013
Clinical Research Facility
510
mi
from 43215
Danbury, CT
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
A Phase 1, Randomized, Double-Blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects, in Subjects With Active Ulcerative Colitis, and in Subjects With Active Crohn's Disease.
Status: Enrolling
Updated: 4/3/2013
Clinical Research Facility
510
mi
from 43215
Danbury, CT
Click here to add this to my saved trials
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
A Phase 1, Randomized, Double-Blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects, in Subjects With Active Ulcerative Colitis, and in Subjects With Active Crohn's Disease.
Status: Enrolling
Updated:  4/3/2013
Clinical Research Facility
993
mi
from 43215
Miami, FL
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
A Phase 1, Randomized, Double-Blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects, in Subjects With Active Ulcerative Colitis, and in Subjects With Active Crohn's Disease.
Status: Enrolling
Updated: 4/3/2013
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
A Phase 1, Randomized, Double-Blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects, in Subjects With Active Ulcerative Colitis, and in Subjects With Active Crohn's Disease.
Status: Enrolling
Updated:  4/3/2013
Clinical Research Facility
243
mi
from 43215
Duncansville, PA
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
A Phase 1, Randomized, Double-Blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects, in Subjects With Active Ulcerative Colitis, and in Subjects With Active Crohn's Disease.
Status: Enrolling
Updated: 4/3/2013
Clinical Research Facility
243
mi
from 43215
Duncansville, PA
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
1959
mi
from 43215
Orange, CA
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
1959
mi
from 43215
Orange, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
2028
mi
from 43215
Roseville, CA
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
2028
mi
from 43215
Roseville, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
1164
mi
from 43215
Littleton, CO
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
1164
mi
from 43215
Littleton, CO
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
539
mi
from 43215
Bristol, CT
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
539
mi
from 43215
Bristol, CT
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
831
mi
from 43215
Tampa, FL
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
604
mi
from 43215
Fort Dodge, IA
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
604
mi
from 43215
Fort Dodge, IA
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
679
mi
from 43215
Topeka, KA
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
679
mi
from 43215
Topeka, KA
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
188
mi
from 43215
Louisville, KY
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
334
mi
from 43215
Laurel, MD
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
334
mi
from 43215
Laurel, MD
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
161
mi
from 43215
Dearborn, MI
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
161
mi
from 43215
Dearborn, MI
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
181
mi
from 43215
Troy, MI
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
181
mi
from 43215
Troy, MI
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
474
mi
from 43215
Mexico, MO
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
474
mi
from 43215
Mexico, MO
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
395
mi
from 43215
St. Louis, MO
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
395
mi
from 43215
St. Louis, MO
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
609
mi
from 43215
Lebanon, NH
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
609
mi
from 43215
Lebanon, NH
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
492
mi
from 43215
Great Neck, NY
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
492
mi
from 43215
Great Neck, NY
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
508
mi
from 43215
Huntington, NY
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
508
mi
from 43215
Huntington, NY
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
481
mi
from 43215
New York, NY
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
350
mi
from 43215
Charlotte, NC
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
350
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
440
mi
from 43215
Kinston, NC
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
440
mi
from 43215
Kinston, NC
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
849
mi
from 43215
Oklahoma City, OK
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
752
mi
from 43215
Tulsa, OK
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
752
mi
from 43215
Tulsa, OK
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
527
mi
from 43215
Charleston, SC
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
527
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
426
mi
from 43215
Columbia, SC
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
426
mi
from 43215
Columbia, SC
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
501
mi
from 43215
Germantown, TN
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
501
mi
from 43215
Germantown, TN
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
331
mi
from 43215
Nashville, TN
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
331
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
1069
mi
from 43215
Austin, TX
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
1069
mi
from 43215
Austin, TX
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
994
mi
from 43215
Galveston, TX
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
994
mi
from 43215
Galveston, TX
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
590
mi
from 43215
Burlington, VT
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
590
mi
from 43215
Burlington, VT
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
241
mi
from 43215
Christiansburg, VA
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
241
mi
from 43215
Christiansburg, VA
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
341
mi
from 43215
Richmond, VA
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
341
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
1998
mi
from 43215
Bellevue, WA
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
1998
mi
from 43215
Bellevue, WA
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
394
mi
from 43215
Madison, WI
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
394
mi
from 43215
Madison, WI
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  4/29/2013
Clinical Research Facility
335
mi
from 43215
Milwaukee, WI
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 4/29/2013
Clinical Research Facility
335
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials